A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : C3G / C3 glomerulopathy

[Related PubMed/MEDLINE]
Total Number of Papers: 61
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   C3G  (>> Co-occurring Abbreviation)
Long Form:   C3 glomerulopathy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Factor B and C4b2a Autoantibodies in C3 Glomerulopathy. ---
2019 Kidney Transplantation in C3 Glomerulopathy: A Case Series. C3GN, DDD
2019 [Membranoproliferative glomerulonephritis and C3 glomerulopathy]. IC-MPGN
2018 An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. FH
2018 Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. C3NeFs, IC, IC-MPGN, MPGN
2018 Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. AP
2018 C3 glomerulopathy associated with monoclonal Igis a distinct subtype. MIg
2018 Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. IC-MPGN, MPGN
2018 Complete functional characterization of disease-associated genetic variants in the complement factor H gene. aHUS, FH
10  2018 Diagnostic accuracy of immunofluorescence versus immunoperoxidase staining to distinguish immune complex-mediated glomerulonephritis and C3 dominant glomerulopathy. CI, ICGN, IF, IP, MPGN
11  2018 Diseases of complement dysregulation-an overview. aHUS, aHUS, PNH, PNH
12  2018 Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration. aHUS, AMD, CFH, CFI, FH, FI, SCR20
13  2018 Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. C3GN, DDD, eGFR, ESRD, MPGN, RAAS
14  2018 Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. ESRD, IC-MPGN, MPGN
15  2018 Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. aHUS, C3NeF, Ig
16  2018 Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. AP, CRIg-Fc
17  2018 Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. aHUS, RVs
18  2018 Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab. ---
19  2018 Treating C3 glomerulopathy with eculizumab. ---
20  2018 Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. C3NeFs, IC, MPGN
21  2017 A haplotype in CFH family genes confers high risk of rare glomerular nephropathies. aHUS, CFH, MPGN I, SPR
22  2017 Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. anti-FB, Ig-MPGN
23  2017 Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. aHUS, KDIGO
24  2017 C3 glomerulonephritis with a severe crescentic phenotype. C3GN, DDD
25  2017 C3 glomerulopathy and current dilemmas. C3GN, DDD
26  2017 C3 glomerulopathy and eculizumab: a report on four paediatric cases. ---
27  2017 C3 Glomerulopathy. AP, IC-GN
28  2017 C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. C4NeFs
29  2017 Characterization of C3 in C3 glomerulopathy. C3GN, DDD
30  2017 Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. ---
31  2017 Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. aHUS, CCP, FH
32  2017 Recurrent glomerular disease after kidney transplantation. aHUS, CKD, FSGS
33  2017 Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. MIg
34  2017 Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. MCD
35  2016 C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. CAP, PIGN
36  2016 C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. AP, C3GN, DDD
37  2016 Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. HUS, Stx, TMA
38  2016 Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces. CFHR
39  2016 Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Ig-MPGN, MPGN
40  2016 Complement inhibition in C3 glomerulopathy. ---
41  2016 Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene. ---
42  2016 Modeling complement-driven diseases in transgenic mice: Values and limitations. aHUS, PNH
43  2016 Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. aHUS, AMD, FH
44  2016 Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. aHUS, AP, FH
45  2016 Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. AP, C3NeF
46  2015 Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. ---
47  2015 Eculizumab for treatment of rapidly progressive C3 glomerulopathy. ---
48  2015 Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. C3GN
49  2015 Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. C3GN
50  2014 C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. C3GN
51  2014 C3 nephritic factor associated with C3 glomerulopathy in children. C3GN, C3NeF, DDD
52  2014 Defining the complement biomarker profile of C3 glomerulopathy. C3GN, DDD
53  2014 Rituximab fails where eculizumab restores renal function in C3nef-related DDD. C3NeF, DDD
54  2014 Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). CFH, MPGN
55  2014 Treatment of C3 glomerulopathy with complement blockers. ---
56  2013 C3 glomerulopathies. A new perspective on glomerular diseases. ---
57  2013 C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. CFHR1, FH, SCRs, SPR
58  2013 Eculizumab and recurrent C3 glomerulonephritis. C3GN, DDD, sMAC
59  2013 Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. aHUS, AMR, C3GN, DDD
60  2013 Treatment options for C3 glomerulopathy. ---
61  2012 Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. MPGN, MPGN I